Aurinia Pharmaceuticals Inc. (AUPH) Stock Price Up 2.2%
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)’s share price rose 2.2% during mid-day trading on Wednesday . The company traded as high as $3.87 and last traded at $3.74, with a volume of 247,329 shares traded. The stock had previously closed at $3.66.
AUPH has been the subject of a number of recent analyst reports. Canaccord Genuity set a $10.00 price target on Aurinia Pharmaceuticals and gave the company a “buy” rating in a report on Friday, August 5th. HC Wainwright initiated coverage on Aurinia Pharmaceuticals in a report on Thursday, June 30th. They set a “buy” rating and a $7.00 price target for the company. Zacks Investment Research raised Aurinia Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, May 24th. Finally, Leerink Swann reaffirmed an “outperform” rating and set a $7.00 price target on shares of Aurinia Pharmaceuticals in a report on Wednesday, July 6th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Aurinia Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $7.15.
The company’s 50-day moving average price is $3.07 and its 200 day moving average price is $2.74. The stock’s market cap is $133.02 million.
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.